Letrozole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Letrozole: From Breast Cancer to Female Breast Carcinoma
One-Sentence Summary
Letrozole is a third-generation aromatase inhibitor already established for the treatment of hormone receptor-positive (HR+) breast cancer. TxGNN’s top-ranked prediction for this drug is Female Breast Carcinoma, supported by an unusually large body of evidence — 60+ clinical trials and 20 publications. However, this “predicted new indication” is functionally identical to letrozole’s well-known existing use, and the evidence pack itself flags a significant data inconsistency that must be resolved before this candidate can be treated as a genuine repurposing opportunity.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (data gap). Letrozole (Femara) is widely known as an aromatase inhibitor for HR-positive breast cancer, but this could not be confirmed from the supplied dataset. |
| Predicted New Indication | Female Breast Carcinoma |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L1 (≥2 completed Phase 3 RCTs) |
| UK Market Status | “Not marketed” per evidence pack — flagged as inconsistent with letrozole’s well-established global/UK marketing status; requires verification |
| Number of Marketing Authorisations | 0 (data gap — see note below) |
| Recommended Decision | Hold — Data Verification Required |
Why is This Prediction Reasonable?
Letrozole is a third-generation, non-steroidal aromatase inhibitor. It blocks the conversion of androgens to oestrogens, lowering both circulating and intratumoural oestrogen levels, thereby suppressing the proliferation of ER-positive breast cancer cells. This is a well-established, extensively validated mechanism.
Important caveat: the disease TxGNN has “predicted” here — Female Breast Carcinoma — is not a novel indication. It is letrozole’s core, already-approved use (marketed globally as Femara). This is not repurposing in the proper sense of the term. The evidence pack’s own scoring rationale explicitly notes this: original_indications is empty and market_status is recorded as “not marketed”, both of which are inconsistent with letrozole’s known regulatory history. This strongly suggests a data-pipeline gap (e.g. missing linkage between the drug record and its approved-indication source) rather than a genuine model-driven discovery.
In practical terms, the very large trial and literature base found for this “candidate” reflects letrozole’s decades of clinical use in breast cancer — not new supporting evidence for an unmet need. We recommend treating this candidate as a data quality flag rather than a repurposing opportunity, and correcting the source records for original indication and UK licensing status before any further evaluation proceeds.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00330317 | Phase 3 | Completed | 300 | Neoadjuvant letrozole in postmenopausal HR+ primary breast cancer; assessed duration of treatment for tumour regression to permit breast-conserving surgery |
| NCT00673335 | Phase 3 | Completed | 170 | Letrozole vs placebo for breast cancer prevention in postmenopausal BRCA1/BRCA2 carriers |
| NCT01626222 | Phase 3B | Completed | 301 | Everolimus + exemestane (4EVER trial) in ER+ postmenopausal women progressing on non-steroidal AI (letrozole-class) therapy |
| NCT00003140 | Phase 3 | Completed | 5,187 | Landmark MA.17 trial: letrozole vs placebo in women completing ≥5 years of adjuvant tamoxifen |
| NCT00248170 | Phase 3 | Completed | 4,172 | Letrozole vs anastrozole as adjuvant treatment in HR+/node-positive postmenopausal breast cancer |
| NCT00754845 | Phase 3 | Completed | 1,918 | Letrozole vs placebo in women who completed 5 years of adjuvant aromatase inhibitor therapy (MA.17-related extension) |
| NCT02338310 | Phase 3 | Active, not recruiting | 4,486 | POETIC: perioperative aromatase inhibitor therapy plus Ki67-guided treatment individualisation |
| NCT04964934 | Phase 3 | Active, not recruiting | 315 | Switching to next-generation oral SERD (camizestrant) vs continuing letrozole/anastrozole + CDK4/6 inhibitor in ESR1-mutated HR+/HER2- metastatic breast cancer |
| NCT03306472 | Phase 2 | Completed | 198 | PIONEER: pre-operative window study of letrozole plus megestrol acetate vs letrozole alone in ER+ breast cancer |
| NCT01439711 | Phase 2 | Completed | 108 | Neoadjuvant letrozole in postmenopausal women with ER+ ductal carcinoma in situ (DCIS) |
Note: these trials reflect letrozole’s established evidence base in breast cancer treatment generally, rather than evidence for a distinct new indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16382061 | 2005 | RCT | New England Journal of Medicine | BIG 1-98 landmark trial comparing letrozole with tamoxifen as adjuvant therapy in postmenopausal HR+ early breast cancer |
| 32683565 | 2020 | RCT | Breast Cancer Research and Treatment | Overall survival results from PALOMA-1: palbociclib + letrozole vs letrozole alone as first-line therapy in ER+/HER2- advanced breast cancer |
| 35464999 | 2022 | RCT | Computational and Mathematical Methods in Medicine | Efficacy, safety and prognosis of sequential tamoxifen–letrozole therapy vs letrozole monotherapy |
| 31838010 | 2020 | RCT | The Lancet Oncology | CORALLEEN: neoadjuvant ribociclib + letrozole vs chemotherapy in luminal B early breast cancer |
| 36243120 | 2022 | Review | Life Sciences | Overview of letrozole pharmacology, toxicity and potential therapeutic effects |
| 20095792 | 2010 | Review | Expert Opinion on Drug Metabolism & Toxicology | Pharmacodynamic, pharmacokinetic, efficacy and safety review of letrozole |
| 16500235 | 2006 | Review | Breast (Edinburgh, Scotland) | Development of letrozole and its use in advanced and neoadjuvant breast cancer |
| 19445563 | 2009 | Review | Expert Opinion on Pharmacotherapy | Comparative review of anastrozole, letrozole and exemestane in early breast cancer |
| 17696797 | 2007 | Review | Expert Opinion on Pharmacotherapy | Present and future role of letrozole in breast cancer treatment |
| 15001182 | 2004 | Review | Women’s Health Issues | Clinical implications and remaining questions from the Letrozole Breast Cancer Trial |
UK Market Information
No marketing authorisation records were returned in this evidence pack (total_licenses: 0, market_status: "Not marketed"). This is flagged as a data gap requiring verification: letrozole is internationally well established as an approved medicine (brand name Femara) for HR-positive breast cancer, and this status should be independently confirmed against the MHRA product database (dmd/SPC repository) before this evidence pack is used for decision-making. Corresponding BNF classification (endocrine therapy, aromatase inhibitor) should also be added once source data is corrected.
Cytotoxicity
Letrozole is an antineoplastic agent by therapeutic classification (aromatase inhibitor, endocrine/hormonal breast cancer therapy), though it is not a conventional cytotoxic chemotherapeutic.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted/endocrine therapy (non-cytotoxic aromatase inhibitor) |
| Myelosuppression Risk | Low — aromatase inhibitors do not act on rapidly dividing marrow precursors; please refer to the SmPC warnings and precautions for confirmation |
| Emetogenicity Classification | Low |
| Monitoring Items | Bone mineral density (long-term oestrogen suppression), lipid profile, liver function; please refer to the SmPC for full monitoring requirements |
| Handling Protection | Standard oral medicine handling; not subject to cytotoxic drug handling regulations (non-cytotoxic hormonal agent) |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold — Data Verification Required
Rationale:
Although the evidence base for letrozole in breast cancer is very strong (L1, multiple completed Phase 3 RCTs), this “predicted new indication” duplicates letrozole’s already-established, globally approved use. The evidence pack itself flags that original_indications is empty and UK market status is recorded as “Not marketed” — both inconsistent with known reality — indicating a data-pipeline gap rather than a genuine repurposing signal. Proceeding on the current dataset risks presenting an already-approved use as a novel discovery.
To proceed, the following is needed:
- Verification and correction of letrozole’s original/approved indication data in the source pipeline
- Confirmation of current UK/MHRA marketing authorisation status and licence numbers (data gap DG001)
- Retrieval of detailed mechanism of action (MOA) data from DrugBank (data gap DG002)
- TFDA/MHRA product label (SmPC) warnings and contraindications for a proper S1 safety screen (data gap DG001, Blocking)
- Re-run of the disease-ontology mapping step to confirm whether “female breast carcinoma” reflects a distinct clinical entity from letrozole’s existing indication, or is an artefact of graph proximity to the drug’s known edges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.